Clinical trialPhase 2Completed
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 18 July 2016
- Expected end
- 1 June 2022
- Enrollment
- 58 participants
- Sites
- 1
- Primary outcomes
- Distant Metastasis Free Survival (DMFS)
- Sponsor
- Other
- Results posted
- 2023-02-28
- Last update
- 13 March 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused radiation) is effective (anti-tumor activity) and safe in patients with locally advanced pancreatic cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Distant Metastasis Free Survival (DMFS) [62 months]. Median, months (95% Confidence Interval). Cyclophosphamide, Pembrolizumab, GVAX Pancreas Vaccine, SBRT (n=54): 9.8 (6.3 to 19.4).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants Experiencing a Grade 3 or Above Treatment Related Toxicities [41 months]. Count Of Participants, Participants. Cyclophosphamide, Pembrolizumab, GVAX Pancreas Vaccine, SBRT (n=58): 11.
Papers 1
- Registry-listed results paperThe combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.